tirzepatide synergy nash In the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once Post-hoc analysis of SYNERGY-NASH trial

STEN EKBERG Get everything you need for optimal hydration and cellular health in one convenient bundle

Additional specificity analysis was conducted to compare the outcomes of GLP-1 RA users with those of patients receiving other second-line antihyperglycemic treatments, including thiazolidinediones (TZDs), DPP-4is, or sulfonylureas (SUs)

Compare tirzepatide 5mg, 10mg, and 15mg doses

Follow muscle and fat separately

No request needed

Its Phase 2 weight loss data (24.2% at 48 weeks) and mechanistic advantages in hepatic fat reduction through glucagon receptor activation suggest it could surpass semaglutide's efficacy if Phase 3 results confirm the Phase 2 findings